A multicenter, prospective randomized controlled study on the effects of dapagliflozin on peritoneal and residual kidney function in peritoneal dialysis patients

Phase 2

• Conditions: peritoneal dialysis

• Registration Number: ChiCTR2400088818
• Lead Sponsor: Army Medical Center of PLA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Age = 18 years old.<br>(2) Patients with PD duration = 3 months.<br>(3) Patients with regular follow-up .<br>(4) Patients who voluntarily participate in this study and sign informed consent forms.

Exclusion Criteria

(1) Patients with type 1 diabetes mellitus.<br>(2) Patients who developed peritonitis within 3 months.<br>(3) Currently receiving SGLT2i treatment or within the past 3 months.<br>(4) Patients with abnormal liver function, including ALT or AST > 3 times the upper limit of normal, or total bilirubin>2 times the upper limit of normal.<br>(5) Recurrent severe hypoglycemia ( more than two episodes during one month).<br>(6) History of diabetes ketoacidosis.<br>(7) Allergic to dapagliflozin.<br>(8) Combined symptomatic urinary tract infections.<br>(9) Patients with combined tumors and severe cachexia.<br>(10) Pregnancy or women who are breast-feeding.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ultrafiltration volume;

Secondary Outcome Measures

Name	Time	Method
Residual renal function;Dialysate glucose;